| Renal Cell Carcinoma
Bavencio vs Lenvima
Side-by-side clinical, coverage, and cost comparison for renal cell carcinoma.Deep comparison between: Bavencio vs Lenvima with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLenvima has a higher rate of injection site reactions vs Bavencio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lenvima but not Bavencio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bavencio
Lenvima
At A Glance
IV infusion
Every 2 weeks
PD-L1 blocking antibody
Oral
Once daily
Multi-kinase inhibitor
Indications
- Merkel cell carcinoma
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Differentiated Thyroid Gland Carcinoma
- Renal Cell Carcinoma
- Liver carcinoma
- Endometrial Carcinoma
Dosing
Merkel cell carcinoma, Urothelial Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks until disease progression or unacceptable toxicity.
Renal Cell Carcinoma 800 mg administered as an intravenous infusion over 60 minutes every 2 weeks in combination with axitinib 5 mg orally twice daily (12 hours apart) with or without food until disease progression or unacceptable toxicity.
Differentiated Thyroid Gland Carcinoma 24 mg orally once daily until disease progression or unacceptable toxicity.
Renal Cell Carcinoma (first-line, with pembrolizumab) 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity or up to 2 years.
Renal Cell Carcinoma (previously treated, with everolimus) 18 mg orally once daily in combination with everolimus 5 mg orally once daily until disease progression or unacceptable toxicity.
Liver carcinoma 12 mg orally once daily for patients >=60 kg or 8 mg orally once daily for patients <60 kg, until disease progression or unacceptable toxicity.
Endometrial Carcinoma 20 mg orally once daily in combination with pembrolizumab 200 mg IV infusion over 30 minutes every 3 weeks until unacceptable toxicity or disease progression.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) fatigue, musculoskeletal pain, diarrhea, hypertension, nausea, rash, infusion-related reaction, cough, constipation, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, hepatotoxicity, dyspnea, abdominal pain, urinary tract infection, headache
Serious immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, myocarditis, neurological toxicities), infusion-related reactions, complications of allogeneic HSCT, major adverse cardiovascular events
Postmarketing neutropenia, sclerosing cholangitis
Most common (>=20%) Hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, dysphonia, hypothyroidism, hemorrhagic events, rash, musculoskeletal pain.
Serious Hepatic encephalopathy, hepatic failure, cardio-respiratory arrest, sepsis, myocardial infarction, pneumonitis, acute kidney injury, renal failure, dehydration, thrombocytopenia, dyspnea, anemia.
Postmarketing Pancreatitis, impaired wound healing, cholecystitis, nephrotic syndrome, arterial aneurysms/dissections/rupture.
Pharmacology
Avelumab is a human IgG1 lambda monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and B7.1 receptors on T cells to restore anti-tumor immune responses; it also induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro.
Lenvatinib is a multi-kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 kinase activities as well as FGFR1-4, PDGFRA, KIT, and RET, suppressing pathogenic angiogenesis and tumor growth; in combination with pembrolizumab or everolimus, it demonstrates enhanced antiangiogenic and antitumor activity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bavencio
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (10/12) · Qty limit (0/12)
Lenvima
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Bavencio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lenvima
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Bavencio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Lenvima
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bavencio.
No savings programs available for Lenvima.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BavencioView full Bavencio profile
LenvimaView full Lenvima profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.